Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
56 hedge funds and large institutions have $92.2M invested in Kinnate Biopharma Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 20 closing their positions.
1% more capital invested
Capital invested by funds: $91M → $92.2M (+$1.13M)
10% less funds holding
Funds holding: 62 → 56 (-6)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
95% less call options, than puts
Call options by funds: $254K | Put options by funds: $5.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
Deltec Asset Management
New York
|
+$2.57M |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$1.23M |
| 3 |
Renaissance Technologies
New York
|
+$774K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$545K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$333K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$5.23M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.02M |
| 3 |
Millennium Management
New York
|
-$737K |
| 4 |
Two Sigma Investments
New York
|
-$710K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
-$687K |
KNTE Hedge Fund Activity: Q1 2024 in Review
56 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q1 2024, worth a combined $92.2M — up 1.2% from $91M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KNTE and 14 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 13 added.
The largest buyer was Deltec Asset Management, opening a new position worth an estimated $2.57M. The largest seller was Vida Ventures Advisors, exiting entirely with an estimated $5.23M sold.
- 56 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q1 2024, down from 62 in Q4 2023.
- Funds reported $92.2M of Kinnate Biopharma Inc. Common Stock stock for Q1 2024, up 1.2% quarter-over-quarter.
- 14 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q1 2024 and 20 closed out, a net change of -6 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q1 2024 was Deltec Asset Management, an estimated $2.57M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q1 2024 was Vida Ventures Advisors, an estimated $5.23M sold.
Based on aggregated 13F filings for Q1 2024.